MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

0.37 5.71

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.36

Max

0.38

Põhinäitajad
By Trading Economics
Sissetulek	983K -47M
Müük	505K 14M
Kasumimarginaal	-342.329
Töötajad	161
EBITDA	-346K -46M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+1089.19% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-30M 75M
Eelmine avamishind	-5.34
Eelmine sulgemishind	0.37

Uudiste sentiment

By Acuity

90%

10%

334 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. apr 2026, 04:27 UTC

Uudisväärsed sündmused

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3. apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 18:30 UTC

Uudisväärsed sündmused

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3. apr 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3. apr 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3. apr 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3. apr 2026, 16:50 UTC

Uudisväärsed sündmused

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3. apr 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 16:12 UTC

Tulu

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

3. apr 2026, 15:20 UTC

Uudisväärsed sündmused

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3. apr 2026, 15:08 UTC

Omandamised, ülevõtmised, äriostud

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3. apr 2026, 14:11 UTC

Market Talk

Uudisväärsed sündmused

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3. apr 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3. apr 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3. apr 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3. apr 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3. apr 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3. apr 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. apr 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3. apr 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3. apr 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3. apr 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3. apr 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

1089.19% tõus

12 kuu keskmine prognoos

Keskmine 4.4 USD 1089.19%

Kõrge 15 USD

Madal 0.3 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

334 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.